RankingsPricing
  1. US-listed companies
  2. Zivo Bioscience, Inc.

Zivo Bioscience, Inc.ZIVO

Market cap
$25.47M
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022
Cash225,69647,147493,1031,383506,986317,135388,891346,111137,86292
Prepaid expenses-----15,143-23,28229,95358,078102,416
Total current assets249,83090,805688,52733,107520,423332,278-369,393167,81592
PROPERTY AND EQUIPMENT, NET83,54613,20393,75068,75018,750------
Operating lease - right of use asset--------49,36427,225189,282
Security deposit---------3,00032,058
Total other assets130,118-1,392,12668,750-----30,225221,340
TOTAL ASSETS463,494234,0042,174,403101,857737,2924,210,079-369,393220,17992
Accounts payable660,565938,640483,2081,225,589666,365541,710-1,372,4281,559,627654,333490,670
Current portion of long-term operating lease--------29,17215,17899,259
Convertible debentures payable---------240,000240,000
Deferred R&D obligations - participation agreements--------1,936,8001525,904
Deferred R&D obligations - participation agreements related parties---------369,037175,427
Accrued interest----2,659,5741,649,240-1,952,6062,464,72495,88698,286
Accrued liabilities - payroll and directors fees75,349270,682738,6861,238,994-10,000-102,500214,250-398,176
Total current liabilities1,788,3363,361,28710,877,4526,233,98311,182,4804,560,803-8,707,87611,393,91532
Long-term operating lease, net of current portion--------15,178-105,919
Total long-term liabilities706,657828,908890,811237,0423,176,04715,953,768--136,878-105,919
TOTAL LIABILITIES2,494,9934,190,19511,768,2636,471,02514,358,52720,514,571-8,707,87611,530,79332
Common stock, $0.001 par value, 150,000,000 and 150,000,000 shares authorized as of December 31, 2022 and December 31, 2021; 9,419,660 and 9,419,660 issued and outstanding at December 31, 2022, and December 31, 2021, respectively100,036105,318116,852128,774136,745141,107-396,737413,0369,4209,420
Additional paid-in capital27,130,27628,448,70532,895,38035,427,33940,016,05947,366,814-81,222,72687,340,025114116
Accumulated deficit-29,261,809-32,510,214-42,606,092-41,925,281-53,774,039-63,812,413--89,957,946-99,063,675-108,227,041-115,804,530
Total stockholders' equity (deficit)-2,031,497-3,956,191-9,593,860-6,369,168-13,621,235-16,304,492--8,338,483-11,310,6146-10,622
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)463,494234,0042,174,403101,857737,2924,210,079-369,393220,17992